Oxaliplatin

Catalog No.S1224 Synonyms: L-OHP

Oxaliplatin Chemical Structure

Molecular Weight(MW): 397.29

Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cleaved caspases and p-H2AX expression were detected by western blot in HCT116 cells (E) and HT29 cells (F). The cells were co-cultured with F. nucleatum or treated with CQ, and different concentrations of Oxaliplatin and 5-FU.

    Cell, 2017, 170(3):548-563.e16. Oxaliplatin purchased from Selleck.

    Immunocytochemical staining of SW620 (metastatic) cells after treatment with 10 uM oxaliplatin (F) or 10 uM ginsenosides 20(S)-Rg 3 (G) and negative staining (H). Cells demonstrated differential expression of histone H4.

    J Proteomics 2014 10.1016/j.jprot.2014.10.009. Oxaliplatin purchased from Selleck.

  • PDT and oxaliplatin combination treatment. A) Bar graph showing response (total volume of residual viale nodules normalized to no treatment control) to PDT treatmen (2.5 J/cm2), oxaliplatin treatment (10 μM), and PDT followed by oxaliplatin at the same doses. The dramatic enhancement, beyond the additive effect of the two modalities independently suggests there may be a synergistic interaction. B) A representative region from a culture stained with calcein AM and ethidium bromide following treatment with the PDT + oxaliplatin combination shows relatively small pockets of viable disease and many dead relative to untreated cultures.

    Optical Methods for Tumor Treatment and Detection 2013 10.1117/12.2010730. Oxaliplatin purchased from Selleck.

     

    Growth inhibitory effects of Oxaliplatin in human pancreatic cancer cells. MiaPaCa-2 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Oxaliplatin (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    2013 Dr. Edita Aksamitiene from Thomas Jefferson University. Oxaliplatin purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells.
Targets
DNA synthesis [1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)
In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. [1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. [2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HKESC-2 MWnDfZRwfG:6aXPpeJkhSXO|YYm= NIPrXokx6oDVMU[wxsDPxE1? NU\YUnBnPDkEoHi= MmfWTWM2OD13LklCpOKyyqByLkWg{txO MXuyOlQ4PDZ7Mx?=
CaES-17 NIjiWY9EgXSxdH;4bYNqfHliQYPzZZk> NXX2[Wd5OOLCk{G2NOKh|ryP NVntdJJVPDkEoHi= MnnrTWM2OD13LkZCpOKyyqByLkKg{txO M4DqfFI3PDd2Nkmz
SW480 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW0PEBpyqB? NYrqOolyUUN3ME2xMlg4KM7:TR?= NVz5dWN2OjZ{Nkm3OVk>
HCT116 NWHP[5FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzpd5c1QCCqwrC= MnrJTWM2OD1zMT64OkDPxE1? NUjnOo5wOjZ{Nkm3OVk>
LoVo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTyfoZ1PDhiaNMg Mn\BTWM2OD17ND64N{DPxE1? NHnYXVgzPjJ4OUe1PS=>
SK-BR-3 M3HoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzlOWNKSzVyPUOxMlAhyrFiMD6xJO69VQ>? MVuyOlIyOTV7MR?=
MCF-7 M{PnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mor1TWM2OD1zNT60JOKyKDBwMzFOwG0> NHm1[IkzPjJzMUW5NS=>
MDA-MB-231 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJ|LkGgxtEhOC5zIN88US=> M1PzVVI3OjFzNUmx
HCT116 p53+/+ M2K1UGZ2dmO2aX;uJGF{e2G7 M2\wc|EwPSEQvF2= M2XNUVI1NzR6IHi= Mo\BbY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?= NWfzSppEOjZ{MEi1NlM>
LoVo  MlfVSpVv[3Srb36gRZN{[Xl? NUTYSJhOOS93IN88US=> M2rPOlI1NzR6IHi= NEP6TVBqdmS3Y3XzJJRz[W6|Y4LpdJRqd26jbDDy[ZBz\XO|aX;uJI9nKESXVD3O NXv0e21OOjZ{MEi1NlM>
SNU-398 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHu3eZJKSzVyPU[uOeKhyrIEoEGuNUDPxE1? M2XPeFI3OTZyNEK5
Hep-G2 NHH1T|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF|LkJCpOKyyqBzLk[g{txO M2nwcFI3OTZyNEK5
SNU-475 NIrEdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|Ux97zgM{Cg{txO MkHXNlYyPjB2Mkm=
SNU-387 M1XrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XRNGlEPTB;MkZCpOKyyqB{Lkeg{txO M{Hmc|I3OTZyNEK5
HT29 NEDQSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[yTWM2OD1yLki4xsDDucLiMD6yJO69VQ>? MVyyOlE1QDV7Nh?=
HCT116 Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC2VVhKSzVyPUCuOFHDqMLzwrCwMlAzKM7:TR?= NVfLR5FGOjZzNEi1PVY>
PA-1 MmjtR4VtdCCYaXHibYxqfHliQYPzZZk> NILwSFYxNTJyIN88US=> NI\NbZIzPC92ODDo NXvJNHdKcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVHzdIF7OjZzM{i2O|E>
OVCAR-5 M3zYb2NmdGxiVnnhZoltcXS7IFHzd4F6 MnKwNE03OCEQvF2= MYSyOE81QC95MjDo NIL0b5VqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUh[W6mIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MYKyOlE{QDZ5MR?=
SK-OV-3 M4TybGNmdGxiVnnhZoltcXS7IFHzd4F6 NHPOdVgxNTFyMDFOwG0> NYnx[m97OjRxNEivO|IhcA>? MUjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MnewNlYyOzh4N{G=
PA-1 M{PORmZ2dmO2aX;uJGF{e2G7 MofENVAh|ryPwrC= M3XGPFI1cA>? MnXueJJq\2encnXzJJRp\SCycn;keYN1cW:wIH;mJJR6eGViSTDJSm5{KGGwZDDjbIVud2urbnXz MXGyOlE{QDZ5MR?=
OVCAR-5 Mk\iSpVv[3Srb36gRZN{[Xl? MoSzN|Ah|ryP NITtZYY1QGh? NFTnXoJ1emmpZ3Xy[ZMhfGinIIDyc4R2[3Srb36gc4YhfHmyZTDJJGlHVnNiYX7kJINp\W2xa3nu[ZM> NH7ldlIzPjF|OE[3NS=>
SK-OV-3 NGnQWXBHfW6ldHnvckBCe3OjeR?= NHXWT5U2OCEQvF2= NF3nfJI6PiCq NUD1OHQyfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6|IHHu[EBkcGWvb3vpcoV{ MV2yOlE{QDZ5MR?=
PA-1 M{TlT2Z2dmO2aX;uJGF{e2G7 NVjEOng4OTBizszNxsA> MWe0PIg> NX;tbZFvfXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| M3LvTVI3OTN6Nkex
OVCAR-5 MU\GeY5kfGmxbjDBd5NigQ>? MYGzNEDPxE1? MWe0PIg> MXX1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM> M{XhblI3OTN6Nkex
SK-OV-3 M3zabGZ2dmO2aX;uJGF{e2G7 NXLiRZhTPTBizszN NXHVbmVIQTZiaB?= NUPOZol2fXBvcnXneYxifGW|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K| M1HSUFI3OTN6Nkex
PA-1 NFT4d2xHfW6ldHnvckBCe3OjeR?= NIHsTYkyOCEQvF5CpC=> MlL0NlRp NWGyZXlSeHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM> MoDwNlYyOzh4N{G=
OVCAR-5 MV3GeY5kfGmxbjDBd5NigQ>? M1S1b|IxKM7:TdMg MkPyNlRp M2XvbZBzd22xdHXzJJNmdnOrdHn2bZR6KG:oIH;2ZZJq[W5iY3HyZ4lvd22jIITvJG5MKGOnbHytcYVlcWG2ZXSgZ5l1d2y7c3nz MV2yOlE{QDZ5MR?=
SK-OV-3 MmXJSpVv[3Srb36gRZN{[Xl? Ml;BOVAh|ryPwrC= NYntc5lMPDhiaNMg MXfwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?= NVTNdo8xOjZzM{i2O|E>
CT26  MoTvSpVv[3Srb36gRZN{[Xl? MmTYOEBuVQ>? M{j2bVQ5KGkEoB?= MVHpcoR2[2W|IHH1eI9xcGGpeR?= NIDxOIszPjF|N{CxNi=>
CT26  MmizSpVv[3Srb36gRZN{[Xl? NHHjNYs1KG2P NEDiV4s1QCCqwrC= M{XWPIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3 MlzsNlYyOzdyMUK=
CT26  MkTaR4VtdCCYaXHibYxqfHliQYPzZZk> NYPWRW8{PCCvTR?= NV:5SFBnPDhiaNMg NHXJfFhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW= M2jHWVI3OTN5MEGy
BE NIf3WmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr6TWM2OD1|LkOzJO69VQ>? MXGyOlAzOzB6NR?=
Colo205 NGj5N|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjEUHVwUUN3ME2zMlM{KM7:TR?= M1vsXFI3ODJ|MEi1
DLD1 M4DQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O4Z2lEPTB;Mj6wNUDPxE1? MlLRNlYxOjNyOEW=
HT29 M1\YZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm4TWM2OD1{Lk[5JO69VQ>? M{XwVVI3ODJ|MEi1
HCT15 NUDVcZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEexU5BKSzVyPUGuOFMh|ryP Mny2NlYxOjNyOEW=
HCT116 MmrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSyd2U1UUN3ME2xMlA1KM7:TR?= M3rMPFI3ODJ|MEi1
HCT116p53- M1jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPNb5VKSzVyPUGuNFgh|ryP MmL0NlYxOjNyOEW=
KM12 M4fCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTRwM{eg{txO NWj3TmlWOjZyMkOwPFU>
LoVo MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUeyNWc5UUN3ME2xMlIh|ryP NVTPTFF1OjZyMkOwPFU>
RKO NYDkXXVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G1T2lEPTB;MT6yN{DPxE1? M3fIPFI3ODJ|MEi1
SW480 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\NTWM2OD1{Lki2JO69VQ>? NGjPVZAzPjB{M{C4OS=>
SW620 NH\kVVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPRTWM2OD1|Lk[4JO69VQ>? NXqwPWdmOjZyMkOwPFU>
MC38 MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\QU|BKSzVyPUKzJO69VSEEsTCy NVrNbo9UOjZyMESwPFQ>
HT29 Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTC[HI3UUN3ME22N{DPxE1iwsGgNVg> M4WyT|I3ODB2MEi0
DLD-1 M4jYSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTN{LkKg{txO NF;Uc2kzPjByM{C4OS=>
HT-29 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwc5p5UUN3ME2zOU43KM7:TR?= MmS4NlYxODNyOEW=
SiHa NXr6XXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwODFCtUAxNjFizszN M2n3ZVI2QDBzMEC3
S3 NIPmXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LQ[WlEPTB;NUOuOUDDuSBzLkWg{txO NIC2Nm0zPThyMUCwOy=>
AGS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXGTWM2OD1zMD62JO69VQ>? M160flI2Pzh7MEW3
MKN-45 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXZbWZUUUN3ME2xOE4xKM7:TR?= MmXjNlU4QDlyNUe=
TMK-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1y0VWlEPTB;MkKuOkDPxE1? NGe0dWwzPTd6OUC1Oy=>
SCM-1 NYf5ZlhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\3NFNKSzVyPUG3MlUh|ryP MnnyNlU4QDlyNUe=
HCT-15 M3TaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXywWZFDUUN3ME24MlY1KM7:TR?= NVrRdHZHOjV5NkG0O|k>
DiFi MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmq4TWM2OD1zMD65OUDPxE1? NHHLdJozPTd4MUS3PS=>
DLD-1 M4na[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRThwNkWg{txO M1WweFI2PzZzNEe5
COLO-320DM NGTHTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXlSo1KSzVyPUWuN|gh|ryP M3X5bFI2PzZzNEe5
SNU-175 M{Dpb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwNUGg{txO MlLHNlU4PjF2N{m=
HT-29 NFLhRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTVwMkKg{txO NXHKWHpROjV5NkG0O|k>
SW620 MWDGeY5kfGmxbjDBd5NigQ>? MUSxNQKBkcL3Zz;tcC=> NHrG[IgzPOLCiXi= M{e1Tolv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG|ZYOgVFYzKGW6cILld5Nqd25? MmHvNlU4PDl2MkC=
SW480 M1PnRmZ2dmO2aX;uJGF{e2G7 MYSxNQKBkcL3Zz;tcC=> MW[yOQKBkWh? NUC1N2lpcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?= MVqyOVc1QTR{MB?=
SW620 NWXX[Vd1TnWwY4Tpc44hSXO|YYm= NUfsSW94OTEkgJpCuYcwdWx? MWqyOQKBkWh? M{C3[YVvcGGwY3XzJINmdGy3bHHyJIF2fG:yaHHnbYMh\my3eB?= NH7qUXkzPTd2OUSyNC=>
SW480 MVfGeY5kfGmxbjDBd5NigQ>? MWqxNQKBkcL3Zz;tcC=> MXuyOQKBkWh? MnO2[Y5p[W6lZYOgZ4VtdHWuYYKgZZV1d3CqYXfpZ{BndHW6 MnLyNlU4PDl2MkC=
A549 NUfDRoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlSVhKSzVyPUWuPEDDuSByLk[g{txO NU\Md29COjV4MkWyOFM>
A549/CDDP NG\IboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYftb5V2UUN3ME2xPE43KMLzIEGuNkDPxE1? NUX2WIVpOjV4MkWyOFM>
Panc-1 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVKyOU82OCEQvF2= NEi0[I4zPC92ODDo NGfifWxqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? MlfiNlU1PDR7MUS=
MIAPaCa-2 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnHHNlUwPTBizszN NIrUWY8zPC92ODDo MWPpcohq[mm2czDwdo9tcW[ncnH0bY9vKG:oIGDDJINmdGy|IHnuJIEhe3mwZYLnbZN1cWNibXHucoVzKGOxbXLpcoVlKHerdHigW2E> NHS3d24zPTR2NEmxOC=>
SW1990 MlXIR4VtdCCYaXHibYxqfHliQYPzZZk> NYf1NIdCOjVxNUCg{txO M3nUXVI1NzR6IHi= NHzGS2tqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? NFHjUnEzPTR2NEmxOC=>
HPDE NGD6TVdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MljXNlUwPTBizszN NHrOWFgzPC92ODDo NHSz[VJqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F? M4DlcFI2PDR2OUG0
Panc-1 NF3JToZCeG:ydH;zbZMhSXO|YYm= NWrKVHVqOjYkgJpCuW0> M2m0UlI1KGh? MoewbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>? M3;nPVI2PDR2OUG0
MIAPaCa-2 NUjvZlVZSXCxcITvd4l{KEG|c3H5 NH:wU3UzPeLCidM1US=> MnvZNlQhcA>? NYfZT4VTcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?= NYTXTlhVOjV2NES5NVQ>
Panc-1 MX7GeY5kfGmxbjDBd5NigQ>? NHLKSowzPeLCidM1US=> M1zQOlI1NzR6IHi= M3HMUIlv\HWlZYOgZ4xm[X[jZ3Wgc4YhWEGUUDygZ4F{eGG|ZT25MEBk[XOyYYPlMVgh[W6mIHPhd5Bie2VvM9Mg NIjJe2szPTR2NEmxOC=>
MIAPaCa-2 M3fvOmZ2dmO2aX;uJGF{e2G7 MX6yOgKBkcL3TR?= MYKyOE81QCCq NEi5S2xqdmS3Y3XzJINt\WG4YXflJI9nKFCDUmCsJINie3Cjc3WtPUwh[2G|cHHz[U05KGGwZDDjZZNx[XOnLURCpC=> M3XOe|I2PDR2OUG0
SW480 M{XIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjTRWxIPzJiaNMg Mn34TWM2OD1zMD63xtEzNjJ4INM1[{9uVA>? NWXhRmlPOjV|NkC2N|E>
HCT116  M2XuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPyO4w4PzJiaNMg NVrFWpdQUUN3ME22MlI{yrFyLke1JOK2\y:vTB?= MYSyOVM3ODZ|MR?=
COC1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR4LkKwxsDDucLiMz6xOEDPxE1? NF;ENXozPTNyN{S0PC=>
SGC7901 NHXDRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjXTWM2OD1{MT63N:KhyrIEoEOuNFgh|ryP M4HncVI2OzB5NES4
A549 NGC2SGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTVzLkC4xsDDucLiMUCuPVYh|ryP MkTFNlU{ODd2NEi=
HepG2 M1S4b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:5eHVrUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN MUGyOVMxPzR2OB?=
MCF-7 NWHUT2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULvN|lJUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN NYLUOXhUOjV|MEe0OFg>
HCT-116 NIHhSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTZwMkVCpOKyyqB{Lkm3JO69VQ>? MoSyNlU{ODd2NEi=
HT-29 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ftZmlEPTB-NUCg{txO NH7nfpczPTNyN{S0PC=>
HEK293 M{G3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRThwOENCpOKyyqB3LkW5JO69VQ>? MmrlNlU{ODd2NEi=
HUVEC MorJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXUTWM2OD1zMT6zNOKhyrIEoEGuNFIh|ryP M1rafFI2OzB5NES4
SW480 NEDYdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17J[lHDqM7:TR?= NVXTSoZJOC15MjDo MmKwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> NIn4SnYzPDl7N{S1NS=>
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH5NeKh|ryP MoO4NE04OiCq MnjIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Ml7BNlQ6QTd2NUG=
HCT116 MkPBSpVv[3Srb36gRZN{[Xl? MX2yM|UhyrWP MV[yOE81QCCq NWDMd2l[e3WycILld5NmeyC|dYL2bZZqdiCvUl7BJIV5eHKnc4Ppc44> MXKyOFc3OTRzMR?=
SW480  NXTYSXBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVu0PEBpyqB? NYfBNZFsUUN3ME2yNE45KHWpL33M NFL0XpEzPDd{ME[3OS=>
SW620 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrUTVZwOTBvN{CgcYcwVA>? M1;Yb|I1NzR6L{eyJIg> NGXpXWtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MXiyOFY1PjNyNR?=
Caco2  M4TZcWZ2dmO2aX;uJGF{e2G7 NXPJW|F1OzEEoN88US=> MUSyOEBp NITDelJFVVOR NIHydpBqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>? M{XvXFI1PTV4NEG1
Caco2  NEW1PJpHfW6ldHnvckBCe3OjeR?= NHnEOHU{NzFyL{OwJO69VQ>? M{LsVVE3KGh? MmjSSG1UVw>? M1fRUYlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEGNUkHDNUwhVlGRMTygTG8uOSxiTWLQNkzDqGGwZF3SVFPDqGSxc3Wt[IVx\W6mZX70cJk> MofGNlQ2PTZ2MUW=
Caco2 NV\KSHZmTnWwY4Tpc44hSXO|YYm= M1fIfVMxNzFyMNMg{txO M3PxUFE3yqCq MUTEUXNQ NELtPIFi[3SrdnH0[ZMhVnKoMh?= Mnu5NlQ2PTZ2MUW=

... Click to View More Cell Line Experimental Data

In vivo A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. [6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C26 colon carcinoma xenografts. [7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. [8]

Protocol

Cell Research:[4]
+ Expand
  • Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method: The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO2 and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 103 cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control
    (Only for Reference)
Animal Research:[6]
+ Expand
  • Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
  • Formulation: Water solution
  • Dosages: 10 mg/kg
  • Administration: A weekly i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro Water 3 mg/mL warmed (7.55 mM)
Ethanol 0.01 mg/mL (0.02 mM)
DMF Insoluble
In vivo Add solvents to the product individually and in order:
5% glucose (with warming)
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 397.29
Formula

C8H14N2O4Pt

CAS No. 61825-94-3
Storage powder
Synonyms L-OHP

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT03050814 Not yet recruiting Colorectal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 3, 2017 Phase 2
NCT02997228 Not yet recruiting Colorectal Adenocarcinoma|High-Frequency Microsatellite Instability|Stage IV Colorectal Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) November 2017 Phase 3
NCT02912559 Not yet recruiting Colon Adenocarcinoma|DNA Repair Disorder|Lynch Syndrome|Microsatellite Instability|Stage IIIA Colon Cancer|Stage IIIB Colon Cancer|Stage IIIC Colon Cancer National Cancer Institute (NCI) September 2017 Phase 3
NCT03043729 Not yet recruiting Rectal Cancer|Rectosigmoid Cancer AIO-Studien-gGmbH|Institut für Klinisch-Onkologische Forschung (IKF) Frankfurt|Sanofi February 2017 Phase 2
NCT03000374 Not yet recruiting Rectal Cancer Grupo Espanol Multidisciplinario del Cancer Digestivo|Pivotal S.L.|Amgen February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is it ok to dissolve Oxaliplatin in DMSO?

  • Answer:

    Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Oxaliplatin | Oxaliplatin supplier | purchase Oxaliplatin | Oxaliplatin cost | Oxaliplatin manufacturer | order Oxaliplatin | Oxaliplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID